Combined treatment of MCF-7 cells with AICAR and methotrexate, arrests cell cycle and reverses warburg metabolism through AMP-activated protein kinase (AMPK) and FOXO1

PLoS ONE

Volumn 11, Issue 2, 2016, Pages

  Fodor, Tamás ^a   Szántó, Magdolna ^a,b   Abdul Rahman, Omar ^a,b   Nagy, Lilla ^a,b   Dér, Ádám ^a   Kiss, Borbála ^a   Bai, Peter ^a,c,d  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b MTA de Cell Biology and Signaling Research Group   (Hungary)

^c MTA DE Lendulet Laboratory of Cellular Metabolism   (Hungary)

^d UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; METHOTREXATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1BETA; TRANSCRIPTION FACTOR FKHR; 5 AMINO 4 IMIDAZOLECARBOXAMIDE; AICA RIBONUCLEOTIDE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CYTOSTATIC AGENT; FORKHEAD TRANSCRIPTION FACTOR; FOXO1 PROTEIN, HUMAN; LACTIC ACID DERIVATIVE; RIBONUCLEOTIDE; TRANSCRIPTION FACTOR; TUMOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; CYTOSTASIS; DRUG POTENTIATION; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GLYCOLYSIS; MCF 7 CELL LINE; METABOLISM; MITOCHONDRIAL RESPIRATION; PROTEIN EXPRESSION; WARBURG EFFECT; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BONE TUMOR; BREAST TUMOR; CELL CYCLE; CELL DIVISION; COMPARATIVE STUDY; DRUG EFFECTS; DRUG SCREENING; ENERGY METABOLISM; ENZYME INDUCTION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MCF-7 CELL LINE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOLECULARLY TARGETED THERAPY; MORTALITY; OSTEOSARCOMA; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

AMINOIMIDAZOLE CARBOXAMIDE; AMP-ACTIVATED PROTEIN KINASES; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; CYTOSTATIC AGENTS; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; ENERGY METABOLISM; ENZYME INDUCTION; FEMALE; FORKHEAD BOX PROTEIN O1; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOLYSIS; HUMANS; LACTATES; MCF-7 CELLS; MEMBRANE POTENTIAL, MITOCHONDRIAL; METHOTREXATE; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; OSTEOSARCOMA; RIBONUCLEOTIDES; RNA INTERFERENCE; TRANSCRIPTION FACTORS;

EID: 84960395715     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0150232     Document Type: Article

References (43)

1. Wallace DC (2012) Mitochondria and cancer. Nat Rev Cancer 12: 685-698. doi: 10.1038/nrc3365 PMID: 23001348
2. Favaro E, Bensaad K, Chong MG, Tennant DA, Ferguson DJ, et al. (2012) Glucose Utilization via Glycogen Phosphorylase Sustains Proliferation and Prevents Premature Senescence in Cancer Cells. Cell Metab 16: 751-764. doi: 10.1016/j.cmet.2012.10.017 PMID: 23177934
3. Icard P, Lincet H (2012) A global view of the biochemical pathways involved in the regulation of the metabolism of cancer cells. Biochim Biophys Acta 1826: 423-433. doi: 10.1016/j.bbcan.2012.07.001 PMID: 22841746
4. Green DR, Galluzzi L, Kroemer G (2014) Cell biology. Metabolic control of cell death. Science 345: 1250256. doi: 10.1126/science.1250256 PMID: 25237106
5. Colombo SL, Palacios-Callender M, Frakich N, Carcamo S, Kovacs I, et al. (2011) Molecular basis for the differential use of glucose and glutamine in cell proliferation as revealed by synchronized HeLa cells. Proc Natl Acad Sci U S A 108: 21069-21074. doi: 10.1073/pnas.1117500108 PMID: 22106309
6. Hardie DG (2007) AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 8: 774-785. PMID: 17712357
7. Bai P, Nagy L, Fodor T, Liaudet L, Pacher P (2015) Poly(ADP-ribose) polymerases as modulators of mitochondrial activity. Trends Endocrinol Metab 26: 75-83. doi: 10.1016/j.tem.2014.11.003 PMID: 25497347
8. Hsu PP, Sabatini DM (2008) Cancer cell metabolism: Warburg and beyond. Cell 134: 703-707. doi: 10.1016/j.cell.2008.08.021 PMID: 18775299
9. Kroemer G (2006) Mitochondria in cancer. Oncogene 25: 4630-4632. PMID: 16892077
10. Faubert B, Boily G, Izreig S, Griss T, Samborska B, et al. (2013) AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In Vivo. Cell Metab 17: 113-124. doi: 10.1016/j.cmet. 2012.12.001 PMID: 23274086
11. Sullivan JE, Brocklehurst KJ, Marley AE, Carey F, Carling D, et al. (1994) Inhibition of lipolysis and lipogenesis in isolated rat adipocytes with AICAR, a cell-permeable activator of AMP-activated protein kinase. FEBS Lett 353: 33-36. PMID: 7926017
12. NCCN-Guidelines (2014) NCCN clinical guidelines in Oncology-Breast Cancer.
13. Feng W, Gentles A, Nair RV, Huang M, Lin Y, et al. (2014) Targeting unique metabolic properties of breast tumor initiating cells. Stem Cells 32: 1734-1745. doi: 10.1002/stem.1662 PMID: 24497069
14. Kim S, Kim do H, Jung WH, Koo JS (2013) Metabolic phenotypes in triple-negative breast cancer. Tumour Biol 34: 1699-1712. doi: 10.1007/s13277-013-0707-1 PMID: 23443971
15. Ayyasamy V, Owens KM, Desouki MM, Liang P, Bakin A, et al. (2011) Cellular model of Warburg effect identifies tumor promoting function of UCP2 in breast cancer and its suppression by genipin. PLoS One 6: e24792. doi: 10.1371/journal.pone.0024792 PMID: 21935467
16. Tang X, Lin CC, Spasojevic I, Iversen ES, Chi JT, et al. (2014) A joint analysis of metabolomics and genetics of breast cancer. Breast Cancer Res 16: 415. doi: 10.1186/s13058-014-0415-9 PMID: 25091696
17. Suhane S, Ramanujan VK (2011) Thyroid hormone differentially modulates Warburg phenotype in breast cancer cells. Biochem Biophys Res Commun 414: 73-78. doi: 10.1016/j.bbrc.2011.09.024 PMID: 21945435
18. Boratko A, Csortos C (2013) NHERF2 is crucial in ERM phosphorylation in pulmonary endothelial cells. Cell Commun Signal 11: 99. doi: 10.1186/1478-811X-11-99 PMID: 24364877
19. Bai P, Bakondi E, Szabo E, Gergely P, Szabo C, et al. (2001) Partial protection by poly(ADP-ribose) polymerase inhibitors from nitroxyl-induced cytotoxity in thymocytes. Free RadicBiolMed 31: 1616-1623.
20. Szántó M, Rutkai I, Hegedus C, Czikora A, Rózsahegyi M, et al. (2011) Poly(ADP-ribose) polymerase-2 depletion reduces doxorubicin-induced damage through SIRT1 induction. Cardiovascular Research 92: 430-438. doi: 10.1093/cvr/cvr246 PMID: 21921080
21. Nagy L, Docsa T, Szαnts M, Brunyαnszki A, Hegedus C, et al. (2013) Glycogen phosphorylase inhibitor N-(3,5-dimethyl-benzoyl)-N'-(β-D-glucopyranosyl)urea improves glucose tolerance under normoglycemic and diabetic conditions and rearranges hepatic metabolism. PLoS One 8: e0069420.
22. Bai P, Houten SM, Huber A, Schreiber V, Watanabe M, et al. (2007) Poly(ADP-ribose) polymerase-2 controls adipocyte differentiation and adipose tissue function through the regulation of the activity of the retinoid X receptor/peroxisome proliferator-activated receptor-gamma heterodimer. JBiolChem 282: 37738-37746.
23. Gyorffy B, Surowiak P, Budczies J, Lanczky A (2013) Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One 8: e82241. doi: 10.1371/journal.pone.0082241 PMID: 24367507
24. Lai L, Leone TC, Zechner C, Schaeffer PJ, Kelly SM, et al. (2008) Transcriptional coactivators PGC-1alpha and PGC-lbeta control overlapping programs required for perinatal maturation of the heart. Genes Dev 22: 1948-1961. doi: 10.1101/gad.1661708 PMID: 18628400
25. Uldry M, Yang W, St-Pierre J, Lin J, Seale P, et al. (2006) Complementary action of the PGC-1 coactivators in mitochondrial biogenesis and brown fat differentiation. Cell Metab 3: 333-341. PMID: 16679291
26. Wareski P, Vaarmann A, Choubey V, Safiulina D, Liiv J, et al. (2009) PGC-1{alpha} and PGC-1{beta} regulate mitochondrial density in neurons. J Biol Chem 284: 21379-21385. doi: 10.1074/jbc.M109. 018911 PMID: 19542216
27. Yadav N, Chandra D (2013) Mitochondrial DNA mutations and breast tumorigenesis. Biochim Biophys Acta 1836: 336-344. doi: 10.1016/j.bbcan.2013.10.002 PMID: 24140413
28. Gonzalez-Angulo AM, Iwamoto T, Liu S, Chen H, Do KA, et al. (2012) Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer. Clin Cancer Res 18: 1109-1119. PMID: 22235097
29. Mouradian M, Kikawa KD, Dranka BP, Komas SM, Kalyanaraman B, et al. (2014) Docosahexaenoic acid attenuates breast cancer cell metabolism and the Warburg phenotype by targeting bioenergetic function. Mol Carcinog: doi: 10.1002/mc.22151
30. Isidoro A, Casado E, Redondo A, Acebo P, Espinosa E, et al. (2005) Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis. Carcinogenesis 26: 2095-2104. PMID: 16033770
31. Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witkiewicz AK, et al. (2009) The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 8: 3984-4001. PMID: 19923890
32. Witkiewicz AK, Whitaker-Menezes D, Dasgupta A, Philp NJ, Lin Z, et al. (2012) Using the "reverse Warburg effect" to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers. Cell Cycle 11: 1108-1117. doi: 10.4161/cc.11.6.19530 PMID: 22313602
33. Pineda CT, Ramanathan S, Fon Tacer K, Weon JL, Potts MB, et al. (2015) Degradation of AMPK by a cancer-specific ubiquitin ligase. Cell 160: 715-728. doi: 10.1016/j.cell.2015.01.034 PMID: 25679763
34. Beckers A, Organe S, Timmermans L, Vanderhoydonc F, Deboel L, et al. (2006) Methotrexate enhances the antianabolic and antiproliferative effects of 5-aminoimidazole-4-carboxamide riboside. Mol Cancer Ther 5: 2211-2217. PMID: 16985054
35. Moncada S, Higgs EA, Colombo SL (2012) Fulfilling the metabolic requirements for cell proliferation. Biochem J 446: 1-7. doi: 10.1042/BJ20120427 PMID: 22835215
36. Bao Y, Mukai K, Hishiki T, Kubo A, Ohmura M, et al. (2013) Energy management by enhanced glycolysis in G1-phase in human colon cancer cells in vitro and in vivo. Mol Cancer Res 11: 973-985. doi: 10. 1158/1541-7786.MCR-12-0669-T PMID: 23741060
37. Zhai X, Yang Y, Wan J, Zhu R, Wu Y (2013) Inhibition of LDH-A by oxamate induces G2/M arrest, apoptosis and increases radiosensitivity in nasopharyngeal carcinoma cells. Oncol Rep 30: 2983-2991. doi: 10.3892/or.2013.2735 PMID: 24064966
38. Inoki K, Kim J, Guan KL (2012) AMPK and mTOR in cellular energy homeostasis and drug targets. Annu Rev Pharmacol Toxicol 52: 381-400. doi: 10.1146/annurev-pharmtox-010611-134537 PMID: 22017684
39. Shackelford DB, Shaw RJ (2009) The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 9: 563-575. doi: 10.1038/nrc2676 PMID: 19629071
40. Canto C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, et al. (2009) AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 458: 1056-1060. doi: 10. 1038/nature07813 PMID: 19262508
41. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, et al. (2006) Resveratrol Improves Mitochondrial Function and Protects against Metabolic Disease by Activating SIRT1 and PGC-1alpha. Cell 127: 1109-1122. PMID: 17112576
42. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, et al. (2005) Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 434: 113-118. PMID: 15744310
43. Ertel A, Tsirigos A, Whitaker-Menezes D, Birbe RC, Pavlides S, et al. (2012) Is cancer a metabolic rebellion against host aging? In the quest for immortality, tumor cells try to save themselves by boosting mitochondrial metabolism. Cell Cycle 11: 253-263. doi: 10.4161/cc.11.2.19006 PMID: 22234241